This site is intended for health professionals only
Thursday 27 June 2019
Share |

Schizophrenia drug "shows promise"

The schizophrenia drug cariprazine being developed by Hungarian producer Richter Gedeon with Forest Laboratories is showing positive phase IIb test results, according to the company.

A spokesman reported: "For the primary endpoint, the Positive and Negative Syndrome Scale (PANSS), the data shows that patients with schizophrenia treated with cariprazine experience significant symptom improvement compared to placebo patients within the first week of treatment and at each subsequent time point studied.

"Based on this latest schizophrenia data, subject to a complete review of the full results, and the previously announced Phase II results in patients suffering from acute mania associated with bipolar I disorder, the companies intend to initiate Phase III trials for both indications in early 2010."

Copyright Press Association 2009

Richter Gedeon

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine